CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma

BackgroundIn clinical applications of CAR T-cell therapy, life-threatening adverse events including cytokine release syndrome and neurotoxicity can lead to treatment failure. Outcomes of patients treated with anti-CD30 CAR T- cell have been disappointing in relapsing/refractory (r/r) classical Hodgk...

Full description

Bibliographic Details
Main Authors: YuanBo Xue, Xun Lai, RuiLei Li, ChunLei Ge, BaoZhen Zeng, Zhen Li, QiaoFen Fu, LiuFang Zhao, SuWei Dong, JinYan Yang, JiYin Guo, QingYin Meng, QingHua Tan, ZhenHui Li, HaiYan Ding, YanLei Zhang, ShaoHui Liu, Alex H. Chang, Hong Yao, RongCheng Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
immunotherapy
classical Hodgkin’s lymphoma (cHL)
CD19
CD30
chimeric antigen receptor (CAR) T-cell
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.607362/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.607362/full

Similar Items